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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYInduced pluripotent stem cells (iPSCs) provide an inexhaustible source of cells for modeling disease and testing drugs. Here we develop a
bioinformatic approach to detect differences between the genomic programs of iPSCs derived from diseased versus normal human
cohorts as they emerge during in vitro directed differentiation. Using iPSCs generated from a cohort carrying mutations (PiZZ) in the
gene responsible for alpha-1 antitrypsin (AAT) deficiency, we find that the global transcriptomes of PiZZ iPSCs diverge from normal con-
trols upon differentiation to hepatic cells. Expression of 135 genes distinguishes PiZZ iPSC-hepatic cells, providing potential clues to liver
disease pathogenesis. The disease-specific cells display intracellular accumulation of mutant AAT protein, resulting in increased autopha-
gic flux. Furthermore, we detect beneficial responses to the drug carbamazepine, which further augments autophagic flux, but adverse
responses to known hepatotoxic drugs. Our findings support the utility of iPSCs as tools for drug development or prediction of toxicity.INTRODUCTION
Alpha-1 antitrypsin deficiency (AATD) is a common ge-
netic cause of both liver and lung disease affecting an esti-
mated 3.4million patients worldwide (de Serres, 2002). The
most common disease variant is caused by an inherited sin-
gle base pair mutation of the SERPINA1 gene that results in
a glutamate to lysine substitution (Glu342Lys) and produc-
tion of a mutant version of the protease inhibitor AAT,
known as Z AAT (Brantly et al., 1988). Z AAT protein is
prone to misfolding and polymerization and has reduced
capacity to inactivate neutrophil elastase, its primary sub-
strate, resulting in both toxic gain-of-function and loss-
of-function phenotypes (Brantly et al., 1988; Crystal,
1990; Lomas et al., 1992; Perlmutter and Pierce, 1989).
AATD has proven difficult to model experimentally in
mice and in human primary or immortalized cells, a factor
that has limited the progress of research aimed either at
elucidating mechanisms of disease or developing new
treatment approaches. Studies based on transgenic PiZStemmice or immortalized cell lines engineered to express the
human mutant Z AAT allele or on primary human hepato-
cytes have provided significant insights into the pathogen-
esis of AATD-associated liver disease. These studies have
demonstrated that polymerization of Z AAT protein in
the ER results in activation of an ER overload response (Hid-
vegi et al., 2005; Lawless et al., 2004), characterized by
chronic activation of the proinflammatory transcription
factor NF-kB (Pahl and Baeuerle, 1995), together with acti-
vation of ER stress-specific caspases (Hidvegi et al., 2005).
Each of these models, however, has shortcomings that
potentially limit its ability to delineate the mechanisms
of a disease that develops over time in human liver tissue.
Recently, the discovery of induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka, 2006) has made it
possible tomodel a variety of genetic diseases in vitro using
patient-derived stem cells (Ebert et al., 2009; Park et al.,
2008; Rashid et al., 2010). The differentiated progeny of pa-
tient-derived iPSCs provide disease-relevant cells in an in-
dividual patient’s genetic background, potentially allowingCell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authors 873
personalized, in vitro assessments of disease pathogenesis
and treatment responsiveness. As with human clinical tri-
als, however, studies utilizing multiple patient-derived
iPSC lines introduce the complexity of genetic variability.
This experimental approach increases the likelihood that
findings will be generalizable to a population rather than
specific to an individual, but also potentially decreases
the signal-to-noise ratio.
Herewe sought to apply an iPSC-based approach to study
generalizable effects of the Z mutation, rather than the
effects of any single individual’s genetic background. To
do so, we incorporated iPSC lines derived from multiple
individuals homozygous for the Z allele (termed PiZZ),
ensuring the inclusion of genetic heterogeneity. We found
that the transcriptional profile of iPSCs derived from indi-
viduals homozygous for the Z allele diverges from normal
controls only upon differentiation to the hepatic stage,
when the AAT gene is expressed. Expression of 135 genes
distinguishes PiZZ iPSC-hepatic cells from controls at
this stage, providing potential clues to liver disease patho-
genesis. PiZZ iPSC-hepatic cells model key features of
AATD-associated liver disease, including intracellular accu-
mulation and reduced secretion of AAT protein as well as
increased autophagic flux. Augmented autophagic flux
can be further enhanced in iPSC-hepatic cells upon treat-
ment with the drug carbamazepine (CBZ), an observation
first made in transgenic PiZ mice (Hidvegi et al., 2010)
that has important implications for treating patients with
AATD-related liver disease. Finally PiZZ iPSC-hepatic cells
exhibit increased sensitivity to a panel of hepatotoxic
drugs, including the common analgesic acetaminophen,
confirming their potential application as tools for drug dis-
covery or prediction of toxicity.RESULTS
To develop iPSC-based model systems of disease, we first
prepared a bank of >60 iPSC clones (ten clones per donor;
partial set and reprogramming methodology described
previously [Mills et al., 2013; Somers et al., 2010]) derived
from the dermal fibroblasts of three control individuals
without any known disease and three recruited volunteers
previously diagnosed with AATD due to homozygous in-
heritance of mutant Z alleles encoding the AAT protease
inhibitor (PiZZ genotype, a common monogenic cause of
hepatic cirrhosis [Eriksson et al., 1986]). Pluripotency of
the resulting cells was confirmed in teratoma assays (Som-
ers et al., 2010), as well as by Pluritest global transcriptomic
analysis (Mu¨ller et al., 2011; Figure S1).
We previously published microarray profiling of the
global transcriptomes of nine iPSC lines made from three
normal donors (three iPSC lines/donor) and three embry-874 Stem Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authoonic stem cell (ESC) lines. We determined that donor-to-
donor genetic variability in stem cell phenotype (defined
as the global transcriptome expressed in the pluripotent/
undifferentiated state) rather than clone-to-clone vari-
ability per donor was most responsible for variance in
gene expression among cell lines (Mills et al., 2013). In
addition to gene expression, we found the propensity to
differentiate into a particular fate was also due mainly to
genetic background as opposed to clonal variability,
consistent with others’ work focused on the relative contri-
bution of donor, cell type of origin, and reprogramming
approach to differentiation efficiency (Kajiwara et al.,
2012). These data prompted us to select only a single clone
per donor for all disease-modeling experiments, as individ-
ual clones of a given genetic background tend to behave
similarly.
PiZZ iPSC-Hepatic Cells Demonstrate Accumulation of
Intracellular AAT Protein and Expression of a
Transcriptomic Disease-Specific Signature
We sought to test the hypothesis that a single transgene-
free iPSC clone from each donor could be used to detect dis-
ease-specific differences between the normal cohort and
the PiZZ cohort, anticipating that differences would
emerge only at a developmental stage in which themutant
AAT gene is expressed. Employing single iPSC clones from
each normal or PiZZ individual as well as normal ESC con-
trol clones (n = 3 per group), we utilized sequential growth
factor stimulation with serum-free conditions that we
established previously (Cheng et al., 2012; Somers et al.,
2010) for the directed differentiation of pluripotent cells
into definitive endoderm followed by early hepatocyte-
like lineages (Figure 1A; Figure S2).
We monitored all nine cell lines across three time points
of hepatic directed differentiation, representing three
developmental stages: (1) undifferentiated (T0), (2) defini-
tive endoderm (T5), and (3) early hepatocyte (T24). No sig-
nificant differences in differentiation efficiency were
observed between PiZZ and normal lines as measured by
flow cytometric quantitation of markers of pluripotency
(SSEA3, TRA-1-81), definitive endoderm (CKIT/CXCR4),
and hepatic (AAT/FOXA1) lineages at each developmental
stage (Figure 1B; Figure S3). As previously reported by
others (Choi et al., 2013; Rashid et al., 2010), we found
intracellular accumulation of AAT protein in all three of
our PiZZ iPSC lines at the hepatic stage (T24). The mean
fluorescence intensity (MFI) of immunostained intracel-
lular AAT protein measured by flow cytometry was loga-
rithmically elevated in iPSC-hepatic cells from three of
three PiZZ individuals compared to the six other lines (Fig-
ures 1B and 1C). This accumulation was neither due to dif-
ferences in AAT (SERPINA1) expression at the RNA level nor
to generalized accumulation of liver-related proteins, suchrs
Figure 1. Patient-Derived PiZZ iPSC-Hepatic Cells Exhibit Intracellular AAT Retention
(A) Schematic overview of iPSC-hepatic directed differentiation protocol. *p < 0.05, **p < 0.01 by one-way ANOVA.
(B) Flow cytometry of fixed, permeabilized iPSC-hepatic cells using anti-AAT and anti-FOXA1 antibodies in nine genetically distinct ESC or
iPSC lines at T24.
(C) MFI of AAT and AFP in PiZZ iPSC-hepatic cells compared to WT iPSC- or ESC-hepatic cells.
(D) Quantification of AAT (SERPINA1) and AFP mRNA levels in iPSC-hepatic cells.
(E) ELISA of secreted AAT and albumin in cell supernatants at T24. *p < 0.05 by two-tailed t test. PS, primitive streak; DE, definitive
endoderm; ACT, Activin A; Chir, Chir99021; OSM, oncostatin M. n = 3 independent experiments. Data are represented as mean ± SEM.as AFP (Figures 1C and 1D). AAT secretion was significantly
decreased in the PiZZ iPSC-hepatic cells while albumin
secretion was similar to controls (Figure 1E), suggesting
that the increase in intracellular AAT was due to a failure
to properly process and secrete this protein.
To address definitively whether accumulation of intra-
cellular protein observed in PiZZ iPSC-hepatic cells was
due to reduced AAT flux and specifically resulted from
the Z mutation, we performed pulse-chase labeling exper-
iments. Employing this classical assay for defining the ki-
netics of AAT protein processing and secretion, we utilized
an AATD iPSC line in which both mutant Z alleles had un-
dergone zinc-finger-mediated gene correction, comparingStemthe corrected clone to its parental, syngeneic PiZZ line
(Yusa et al., 2011). Published studies in PiZ mice (Graham
et al., 1990), HeLa cells (Hidvegi et al., 2005), and primary
human fibroblasts (Wu et al., 1994) engineered to express
the mutant Z protein previously have demonstrated
altered posttranslational modification of AAT protein
and delayed secretion in Z AAT-expressing cells. In
keeping with these heterologous models, we found de-
layed processing of the native 52-kDa AAT protein to
its mature 55-kDa form in PiZZ iPSC-hepatic cells
together with delayed AAT secretion compared to its
gene-corrected parental line and a wild-type (WT) control
line (Figures 2A–2C).Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authors 875
Figure 2. Pulse-Chase Radiolabeling
Demonstrates Altered Post-translational
AAT Processing and Secretion Kinetic in
PiZZ iPSC-Hepatic Cells
(A) Quantification of radiolabeled AAT
protein from cell lysates or supernatants at
indicated time points after 35S-Met/Cys
radiolabeling. Both the 52-kDa native AAT
protein and its 55-kDa mature are detected
in WT, PiZZ, and gene-corrected PiZZ (to
PiMM, following ZFN-mediated correction of
the Z mutation) iPSC-hepatic cells.
(B) Kinetic of aggregate cell lysate and
supernatant radiolabeled AAT secretion
data represented in (A).
(C) Quantification of aggregate intracellular
radiolabeled AAT protein during the chase
period. n = 4 (PiZZ) or n = 3 (PiZZ corrected/
WT) independent experiments. Data are
represented as mean ± SD. *p < 0.05, **p <
0.01, ***p < 0.001 by two-tailed t test.Having demonstrated decreased AAT protein flux and
intracellular AAT accumulation in disease-specific iPSC-he-
patic cells, we next performed microarray analyses of the
global transcriptomes (mRNA and microRNA [miRNA])
and DNA methylomes (methylated CpG dinucleotides) of
these nine cell lines at each differentiation stage (Figure 3).
Principal component analysis (PCA) ofmRNA,miRNA, and
DNAmicroarrays from these 27 samples revealed tight clus-
tering of samples by developmental stage rather than by
donor (Figure 3A). To statistically interrogate the kinetics
of global gene expression of each cell line during directed
differentiation to liver, we employed two-way ANOVA of
all 27 samples to identify: (1) genes that are differentially
expressed among days 0, 5, and 24 of differentiation
(time effect); (2) genes that are differentially expressed
among ESC, normal iPSC, and PiZZ iPSC lines (cell type
effect); and (3) gene expression differences among cell
types that are modulated by differentiation (interaction
effect of cell type and time). We have described previously
this approach of comparing the entire gene expression ki-
netic with differentiation as a robust method for detecting
subtle differences between iPSCs and ESCs when using
small sample sizes (Christodoulou et al., 2011). Directed
differentiation was associated with a large number of
gene expression changes (11,232 of 30,000 probe sets
were significantly associated with the time effect at false
discovery rate (FDR) < 0.01; Figure 3B). Importantly, all
master endodermal transcriptional regulators assessed876 Stem Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Autho(FOXA2, GATA4 and 6, SOX17, HEX, and HNF4A) were
upregulated as expected at T5, and knownmarkers of hepa-
tocytes (AAT, TTR, FBG, TF, ALB, CYP450 enzymes, and
hepatitis virus receptors) were upregulated at T24 (Fig-
ure 3B; Figure S2). As expected, AAT was not detectably
expressed at T0 or T5; however, AAT was the third most
significantly upregulated gene of 30,000 tested transcrip-
tomic probe sets in the genome at the hepatic stage
(ranking by FDR-adjusted p value; Figure 3B).
To develop a putative PiZZ disease-specific transcrip-
tomic signature based on this iPSC model of differentia-
tion, we next analyzed the interaction effect. We identified
differentially expressed genes based on the interaction of
time and cell type (419 genes at FDR < 0.25; Figure 3C; 85
genes at FDR < 0.1). To determine which cell type and dif-
ferentiation stage were responsible for differences in gene
expression during directed differentiation, we first em-
ployed unsupervised clustering of the top 1,000 genes
differentially expressed with time, and we found the 27
samples clustered predominantly by developmental stage.
However, clustering by cell type emerged at the hepatic
stage of differentiation based on the height of the clustered
dendogram at T24 (Figure 3B). Second, we performed a post
hoc analysis of the cell type effect usingmoderated t tests to
identify which cell type was responsible for the cell type
effect. These tests revealed that the cell type effect was
due entirely to the PiZZ iPSC clones, with no cell type dif-
ferences between ESCs versus normal iPSCs. Third, wers
performed post hoc moderated t tests of the interaction
effect to identify 135 differentially expressed transcripts
at T24 that distinguished normal versus PiZZ iPSC-hepatic
cells, hereafter referred to as a disease-specific transcrip-
tomic signature (Figure 3D; Table S1). The five genes
most differentially expressed in this list were then validated
by qPCR (DNAH5, CASP4, CFH, HAVCR2, and ERAP2;
Figures 3D and 3E). Together these statistical analyses
indicated that the subtle divergence in gene expression
kinetics among cell types undergoing hepatic directed
differentiation is due mainly to the divergence of PiZZ dis-
ease-specific clones upon reaching the hepatic stage (Fig-
ures 3C and 3D).
We next looked at differences in miRNA (by miRNA
arrays) and methylation status (by genome-wide Illumina
450Kmethylation array) of ESCs and iPSCs during directed
differentiation. The large variance in miRNA expression
profiles precluded finding any statistically significant
miRNA expression differences between diseased and
normal cells at any stage; however, clear differences were
evident in all cell types based on developmental stage
(Table S2; Figure 3A). In keepingwith themRNA expression
differences that emerged between PiZZ iPSCs versus normal
iPSCs and ESCs during directed differentiation, the number
of DNA methylation differences between diseased and
normal pluripotent stem cells also increased from 23 at
T0 to 195 at T24 (Table S2). To determine whether differ-
ences in DNA methylation could potentially account for
altered gene expression in PiZZ iPSC-hepatic cells, we
next analyzed CpG sites in the promoter regions of differ-
entially expressed genes (Figure 3A). At the hepatic stage
(T24), one ormoreCpG sites were differentiallymethylated
in 13 of the 135 interaction effect genes (Table S3)
comprising the PiZZ disease-specific transcriptomic signa-
ture. CpGmethylation and expression levels of these genes
were significantly anti-correlated. While not in themselves
proof of causality, together these findings suggest an
association between differences in gene expression in
hepatic-stage PiZZ and normal iPSCs and alterations in
the methylation state of the promoter regions of a subset
of these genes.
Hepatic Pathways Responding to Intracellular
Accumulation of Mutant Z AAT
Next we sought to employ our disease-specific transcrip-
tomic signature and the iPSCmodel system to better under-
stand the pathogenesis of AATD-related liver disease. Based
on established mouse models, human liver biopsy speci-
mens, and human heterologous cell line studies, mutated
Z AAT protein has been demonstrated to induce liver
disease through a toxic gain-of-function resulting predom-
inantly from the accumulation of misfolded, insoluble ag-
gregates of mutant protein in the rough ER (Lomas et al.,Stem1992). Indeed, our interaction effect gene signature re-
vealed differential expression of several individual gene
markers associated with oxidant stress or known to localize
to the ER. For example, 27 genes on the interaction
list, including ERAP2, were grouped under the gene
ontology heading of ER (Figure 3; Table S1). Notably, the
second most significantly differentially expressed tran-
script within the interaction effect disease-specific signa-
ture was the ER stress-specific caspase family member,
caspase-4, validated by qPCR to be upregulated in PiZZ
iPSC-hepatic cells compared to controls (Figure 3E). Activa-
tion ofmouse caspase-12 andhuman caspase-4, its putative
homolog (Hitomi et al., 2004), have been demonstrated in
Z AAT-expressing mouse and human cell lines and in PiZ
mouse livers (Hidvegi et al., 2005).
Markers of the unfolded protein response (UPR) were not
present in the PiZZ disease-specific signature in concor-
dancewith previous studies that have detected no evidence
of hepatic UPR resulting from misfolded Z AAT in mouse
models or cell lines or human liver biopsy specimens
(Hidvegi et al., 2005). Since T24 represents a time in
culture >1 week after the onset of initial AAT protein
expression (Figure S3), we sought to determine whether a
UPR was detectable in the disease-specific cells closer to
the time of initial expression of the mutant Z AAT protein.
Indeed, by qPCR at T18 of differentiation, we found signif-
icant upregulation of ATF4 and spliced XBP-1 mRNA only
in the PiZZ cells (Figure 3F). To evaluate whether these find-
ings extended to differences in protein expression, we next
performed western blots on whole-cell lysates collected
from T16–T18 cells, and we found increased levels of
spliced XBP-1 and the ER resident chaperone molecule
Grp-78 in PiZZ cells compared to controls. Because the
UPR is likewise known to activate NF-kB via degradation
of its inhibitor, IkBa, mediated by IRE-1 oligomerization
and binding to TRAF2 (Kaneko et al., 2003), we also assayed
IkBa and found it to be decreased in PiZZ cells at this stage
of differentiation (Figure 3G; Figure S4). Together, these
findings are consistent with activation of the UPR in hepa-
tocytes by misfolded Z AAT protein, potentially in a
manner that is context specific.
The autophagy pathway is a key cellular mechanism
thought to be responsible for processing intracellular Z
AAT protein aggregates, based on documented increases
in autophagic flux in mammalian cell lines and mouse
models featuring overexpression of human Z AAT (Teck-
man and Perlmutter, 2000; Teckman et al., 2002). Indirect
evidence of altered autophagy in humans derives from
observation of increased numbers of autophagic vesicles
in PiZZ liver biopsy specimens (Teckman and Perlmutter,
2000). We therefore sought to monitor and manipulate
autophagic flux in iPSC-derived hepatic lineages. We first
transduced PiZZ versus normal iPSC-hepatic cells with aCell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authors 877
Figure 3. Genome-wide Transcriptomic and Epigenomic Analysis of PSCs at Key Developmental Stages
ESCs (n = 3) and patient-derived normal/WT (n = 3) or PiZZ (n = 3) iPSCs were analyzed at T0, T5, and T24 for a total of 27 samples.
(A) PCA demonstrates clustering predominantly by developmental stage (arrows indicate hepatic-stage PiZZ cells).
(B) Unsupervised hierarchical clustering of 27 samples analyzed by two-way ANOVA for time and cell type effects demonstrates differential
gene expression with directed differentiation. The top ten genes upregulated with differentiation (middle) as well as expression levels of
select endoderm genes at T5 (bottom) are listed.
(C) Analysis of gene expression differences among cell types that are modulated by differentiation (interaction effect of time and cell type)
reveals 419 differentially expressed genes (FDR < 0.25; 85 genes at FDR < 0.1).
(D) Expression levels of the top five genes differentially expressed between PiZZ and normal iPSC-hepatic cells as identified by a post hoc
moderated t test of the interaction effect gene set.
(E) qPCR validation of relative mRNA expression levels of genes from (D). n = 3 independent experiments. *p < 0.05 by two-tailed t test.
(legend continued on next page)
878 Stem Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authors
Figure 4. Enhanced Autophagic Flux in
PiZZ iPSC-Hepatic Cells
(A) Differentiating iPSCs were transduced
with a lentivirus encoding an LC3-GFP
fusion protein. Following differentiation to
the hepatic stage, LC3-GFP+ autophago-
somes are quantified in the presence or
absence of bafilomycin, an inhibitor of
lysosomal fusion. Data are representative of
one to three biological replicates per group
per condition. Scale bars, 50 mM.
(B) Protein levels of the autophagosome
components LC3-I and -II, together with
p62 are quantified by western blot in WT and
PiZZ iPSC-hepatic cells in the presence and
absence of CBZ treatment.
(C) Protein levels from (B) are displayed
graphically and normalized to actin (n = 3
biological replicates per group). Data are
represented as mean ± SEM. ***p < 0.001
by two-tailed t test.lentiviral LC3-GFP reporter (Twig et al., 2008) to count
autophagosomes per cell. After treating T18 cells for 1 hr
with the autophagosome clearance blocker bafilomycin,
we observed more autophagosomes per cell in the PiZZ
group (n = 50–60 cells per group; Figure 4A). Because these
findings are consistent both with increased autophago-
some formation and clearance in PiZZ iPSC-hepatic cells,
we next determined LC3-I, LC3-II, and p62 protein levels
in iPSC-hepatic cells by western blot analysis (Figures 4B
and 4C). We found decreased p62 and decreased LC3-I
with no significant changes in LC3-II in PiZZ iPSC-hepatic
cells compared to controls, indicating increased clearance
of autophagosomes in PiZZ cells. Together, these data indi-
cate that increased autophagic flux is present in the PiZZ
iPSC-hepatic cells, consistent with prior studies in other
models (Hidvegi et al., 2010; Teckman and Perlmutter,
2000).
To determine whether drug treatment could further
augment autophagic flux in iPSC-hepatic cells, we em-
ployed CBZ treatment based on publications by Perlmutter
et al. who found this drug augments flux and reduces the(F) qPCR quantification of ATF4 and spliced XBP-1 mRNA expression a
independent experiments. *p < 0.05 by one-way ANOVA.
(G) Densitometric quantification of sXBP-1, Grp78, and IkBa protein e
PiZZ and normal iPSCs (n = 3 biological replicates per group) at T16–T
Stemburden of accumulated intracellular Z AAT protein in trans-
genic mice and heterologous cell lines. We observed
increased LC3-II and LC3-I in both normal and PiZZ
iPSC-hepatic cells, indicating increased autophagosome
formation with CBZ treatment. The differences between
normal and PiZZ cells were maintained after treatment,
indicating increased clearance and increased formation of
autophagosomes in PiZZ cells. However, the increase in
p62 after CBZ treatment, likely resulting from increased
autophagosome formation and accumulation, was greater
in normal cells (40%) than in PiZZ cells (10%) (Figures
4B and 4C). Together, these findings provide evidence in
human patient samples that supports and extends findings
from prior non-human model systems demonstrating
increased baseline autophagic flux in PiZZ-producing cells
that is further augmented by CBZ.
iPSC-Hepatic Cells Serve as a Model of Disease-Specific
Drug Therapy
Having demonstrated that CBZ is able to augment auto-
phagic flux in human iPSC-hepatic cells, we next soughtt early hepatic stage (T18) in ESCs and PiZZ or normal iPSCs. n = 3
xpression levels by western blot of whole-cell lysates prepared from
18 and normalized to GAPDH. Data are represented as mean ± SEM.
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Figure 5. PiZZ and WT iPSC-Hepatic Cells Diverge in Their Response to Drug Treatment
(A) Representative flow cytometric analysis of AAT MFI in WT and PiZZ iPSC-hepatic cells (T24) following a 48-hr treatment with control
vehicle or CBZ.
(B) Aggregate data from three WT and three PiZZ lines, including data represented in (A), are quantified graphically. n = 3 independent
experiments.
(C) AAT (SERPINA1) (top) and AFP (bottom) mRNA expression levels with and without CBZ treatment, expressed as a percentage of un-
treated levels.
(D) Concentration of AAT (top) and albumin (bottom) in iPSC-hepatic cell supernatants measured by ELISA. n = 3 independent
experiments.
(E) Viability of PiZZ and WT iPSC-hepatic cells is quantified by MTT assay after incubation with acetaminophen (4 hr) or aflatoxin B,
amiodarone, danazol, or puromycin (4 days) at the indicated concentrations. Survival percentage at each concentration is determined as a
percentage of vehicle control treatment. n = 3 independent experiments. Data are represented as mean ± SEM. P values represent
contribution of cell type to variance as determined by two-way ANOVA.to determine whether augmented flux would decrease
intracellular AAT accumulation in PiZZ cells. We found all
three PiZZ donor lines demonstrated CBZ dose-dependent
amelioration in accumulation of intracellular AAT protein,
whereas no significant difference was observed in the low
levels of intracellular AAT in normal cells before versus after
treatment (Figures 5A and 5B; Figure S5). CBZ treatment880 Stem Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authodid not result in changes in expression of AAT or differen-
tiation marker genes, indicating that the observed reduc-
tion in intracellular AAT was not due to the inhibition of
AAT transcription or to suppressed hepatic differentiation
of iPSCs (Figure 5C). Finally, CBZ did not affect levels of
secreted AAT (or an alternative hepatic secreted protein,
albumin) in iPSC-hepatic cell supernatants (Figure 5D).rs
PiZZ iPSC-Hepatic Cells Display Increased
Susceptibility to Drug-Induced Toxicity
A hallmark of diseased hepatocytes in humans is increased
susceptibility to environmental insults or drug toxicity
compared to normal hepatocytes. While iPSC-hepatic cells
recently have been evaluated as a potential platform for
detecting drug toxicity (Sjogren et al., 2014; Szkolnicka
et al., 2014), the relative sensitivity of diseased and normal
differentiated iPSCs to hepatotoxic agents has not to our
knowledge been examined. Hence, we sought to test
whether PiZZ iPSC-hepatic cells are more susceptible to
the toxic effects of a common pharmaceutical analgesic,
acetaminophen. Indeed, we found PiZZ iPSC-hepatic cells
were more susceptible to acetaminophen-induced toxicity
than normal controls, as evidenced by lower viability at
each dose of acetaminophen tested (Figure 5E). To evaluate
the specificity of this finding, we extended our evaluation
to include a panel of four additional drugs (amiodarone,
danazol, puromycin, and aflatoxin-B) known to cause hep-
atotoxicity through several mechanisms. In each case, PiZZ
cells were more sensitive than normal control iPSC-hepatic
cells to drug-induced toxicity, consistent with a broad sus-
ceptibility to hepatotoxic agents (Figure 5E).DISCUSSION
In summary, our results demonstrate the application of
iPSCs from multiple donors to model disease, predict
drug efficacy or toxicity, and unveil mechanisms not easily
studied in vivo in humans or mouse models. We present a
bioinformatic approach to defining disease-specific signa-
tures for monogenic diseases based on the delineation of
a global transcriptomic signature that emerges in diseased
cells only upon reaching the developmental stage at which
the mutant protein is expressed. Using this approach, we
found PiZZ iPSC lines did not differ from control iPSCs or
ESCs when in the undifferentiated or endodermal states
but diverged at the hepatic stage, exhibiting evidence of
intracellular accumulation of mutant AAT protein, a tran-
scriptomic disease-specific signature that likely represents
the downstream effect of accumulated protein aggregates,
and activation of pathways known to respond to
the burden of misfolded intracellular protein, such as
augmented autophagic flux.
In these studies, we included multiple donors in each
cohort, rather than multiple isogenic clones, in an
approach intended to mimic the design of human clinical
trials. This allowed us to determine whether, within a
genetically diverse cohort, we could detect disease-specific
differences emerging above the known phenotypic varia-
tion among normal individuals. Indeed, we were able to
detect disease-state-specific differences in gene expressionStemamong cohorts, in addition to some differences in levels
of intracellular protein accumulation among clones, that
could represent genetic differences in protein processing
or the cellular response to misfolded proteins that has
been postulated to exist among individuals (Pan et al.,
2009; Wu et al., 1994).
Human iPSC-hepatic cells derived using our differentia-
tion protocol were similar to primary human fetal hepato-
cytes in terms of expression levels of a subset of hepatic
genes. These results are consistent with other published
protocols (Rashid et al., 2010; Si-Tayeb et al., 2010) demon-
strating differentiation of hepatic cells that were incom-
plete in their maturity, as evidenced by persistent, high
levels of AFP expression that were similar to fetal levels in
our experiments. This hurdle in directing differentiation
of pluripotent stem cells to fully mature differentiated cells
has been seen across germ layers and cell types (Baxter
et al., 2015; Smith et al., 2013), reflects the general state
of the field, and is the focus of a growing number of inves-
tigators (Ogawa et al., 2013; Shan et al., 2013). As our data
and the published literature suggest (Leung et al., 2013;
Rashid et al., 2010; Suzuki et al., 2014), however, the ability
to fully mature a cell in vitro might not be necessary to
model and study key disease features when disease-causa-
tive genes are expressed at high levels.
We used our iPSC human disease model to assess both
well-accepted and controversial pathways for handling
proteinmisfolding that have been interrogated using other
approaches. Our report utilizes the classical pulse-chase
labeling technique to quantify the kinetics of AAT process-
ing and secretion using human patient-derived hepato-
cyte-like cells, demonstrating the ability of iPSC-hepatic
cells tomodel a key feature of Z AAT protein-driven cellular
dysfunction. In cells accumulating misfolded, insoluble Z
AAT protein polymers, the autophagy pathway is activated
in an attempt to deal with this toxic protein accumulation.
Our studies document increased formation as well as
increased clearance of autophagosomes in PiZZ iPSC-
hepatic cells, consistent with augmented autophagic flux.
These findings are in accordwith those previously observed
in mouse embryonic fibroblasts (MEFs), cell lines, and
transgenic mice overexpressing human Z AAT. Increased
autophagosome numbers have been observed in liver
biopsy specimens from PiZZ individuals (Teckman and
Perlmutter, 2000), but it has not been possible previously
to measure flux in their tissues. Our report extends to
human hepatic cells the observation made in PiZ trans-
genic mice (Hidvegi et al., 2010) that further CBZ-induced
augmentation of this flux ameliorates intracellular accu-
mulation of mutant protein.
A second cellular stress pathway implicated in the setting
of accumulated intracellular Z AAT protein is the UPR,
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and downstream development of liver disease, a poorly
understood progression (Lawless et al., 2004; Perlmutter
et al., 2007). Previous studies of PiZZ liver disease in other
model systems have not detected a UPR, despite its known
role in the cellular response to high volumes of proteinmis-
folding (Hidvegi et al., 2005). Our detection of a UPR, early
during the hepatic differentiation of PiZZ iPSCs, thus con-
trasts with these studies, though it is in keeping with recent
patient-based findings in circulating monocytes from PiZZ
individuals (Carroll et al., 2010).
The potential of iPSC-based prediction of drug toxicity is
a topic that has generated wide interest as protocols for
directed differentiation have progressed. Our finding that
PiZZ iPSC-hepatic cells exhibit increased sensitivity to an
assortment of hepatotoxic drugs, including the analgesic
acetaminophen, are in accord with the common clinical
recommendation that patients with liver disease limit acet-
aminophen intake and suggest the possibility that they
may be at risk from other medications as well. While our
findings likewise reinforce the potential application of
iPSC-derived cell types for drug toxicity testing, further
studies to evaluate mechanisms by which specific agents
induce toxicity in iPSC-hepatic cells versus primary human
hepatocytes are likely to be important in understanding
their predictive capacity (Sjogren et al., 2014).
In summary, our findings provide both global, genome-
wide and focused, pathway-based views of disease-specific
iPSCs as they differentiate in vitro into a target lineage
responsible for AATD pathogenesis in patients. Our results
provide comprehensive genetic and epigenetic databases
for those interested inmodelinghumanendodermand liver
development or liver disease onset. Future work can now
focus on testing whether iPSC lines derived from each indi-
vidual patient also have the capacity to model distinct
patient-to-patient disease severity and clinical phenotypes
known to occur among individuals with the same mono-
genic AATD mutation. Our results demonstrating drug re-
sponses in AATD iPSC-hepatic cells also raise the important
question of whether individual patient iPSC lines also
might predict in vivo individual therapeutic responses or
toxicities to drugs, a hypothesis that will likely be tested in
partnership with clinical drug trials in the years ahead.EXPERIMENTAL PROCEDURES
Production, Characterization, and Maintenance of
PSCs
The recruitment of human subjects and all iPSC studies were
approved by the Boston University Institutional Review Board
(BUMC IRB H-27636). Human dermal fibroblast-derived iPSCs
were generated and characterized to confirmpluripotency as previ-
ously described (Mills et al., 2013; Somers et al., 2010; Terrenoire
et al., 2013). Where indicated, clones underwent additional evalu-882 Stem Cell Reports j Vol. 4 j 873–885 j May 12, 2015 j ª2015 The Authoation by pluripotency array scores. iPSC and ESC lines were main-
tained in a 5%CO2 air environment in human iPSCmedia (Somers
et al., 2010). iPSC clones underwent a minimum of 20 passages
prior to additional experimentation. Additional details are
described in the Supplemental Experimental Procedures.
Directed Endodermal and Hepatic Differentiation of
PSCs with Flow Cytometry Sorting/Analysis
Human PSCs were differentiated via the serial introduction of
growth factors using previously described endodermal and hepatic
differentiation protocols (Cheng et al., 2012). Additional details of
the protocol and antibody staining procedures for flow cytometry
and cell sorting are described in the Supplemental Experimental
Procedures.
ELISA
Secreted AAT and albumin were quantified in the supernatants of
differentiated PSCs as previously described (Wilson et al., 2008,
2010). Human albumin was quantified using the Abcam Albumin
Human ELISA kit per the manufacturer’s instructions.
RNA Isolation and qPCR Analysis
Total RNA and miRNAwere isolated from cells using an miRNeasy
kit (QIAGEN) according to the manufacturer’s instructions. Hu-
man fetal liver control RNA was purchased from Clontech Labora-
tories. Real-time qPCR was performed in triplicate for all samples
using either the SYBR Green or TaqMan systems as previously
described (Mills et al., 2013; Somers et al., 2010). Additional details
are described in the Supplemental Experimental Procedures.
Gene Expression and DNA Methylation Microarray
Analysis
Large and small RNAs were labeled with biotin before hybridiza-
tion to Affymetrix GeneChip Human Gene 1.0 ST or miRNA 2.0
arrays and analyzed using previously published methods (Mills
et al., 2013). miRNA 2.0 arrays were normalized to produce probe-
set-level expression values using the Affymetrix miRNA QC
Tool (version 1.1.1.0), using default background detection, RMA
global background correction, quantile normalization, and me-
dian polish summarization. Quantitative measurement of DNA
methylation in study samples was achieved using Illumina’s
Infinium HD Methylation Assay with HumanMethylation 450
BeadChip arrays. Additional details are described in the Supple-
mental Experimental Procedures.
Statistical Analysis
PCA was performed using the prcomp R function with expression
values normalized across all samples to a mean of zero and an SD
of one. Differential gene expression was assessed using limma
(version 3.14.4) by modeling expression as a linear function of
cell type, time, and their interactionwith lmFit, followed by adjust-
ment with eBayes. Two-way ANOVA and moderated t tests were
then performed using the limma functions topTableF and topTable,
respectively. Correction for multiple hypothesis testing was
accomplished using Benjamini-Hochberg FDR. All analyses were
performed using the R environment for statistical computing.rs
AAT Pulse-Chase Radiolabeling
iPSC line B-16 and its isogenic, zinc-finger nuclease (ZFN)-cor-
rected daughter iPSC line B-16-C-2 were differentiated to the
hepatic stage before labeling with 35S-Met/Cys. The kinetic of
AAT post-translational intracellular processing and secretion was
then assayed via pulse-chase labeling using previously described
methods (Ordo´n˜ez et al., 2013). Additional details are described
in the Supplemental Experimental Procedures.
Quantification of Autophagic Flux
To quantify autophagosomes in differentiating iPSC-hepatic cells,
T9 PiZZ or WT cells were transduced overnight with an LC3-GFP
encoding lentivirus at anMOI of 12.5 in differentiationmedia con-
taining polybrene (5 mg/ml). Cells were then differentiated until
T16 before treatment with either CBZ (30 mM) or DMSO vehicle
for 48 hr. At T18, live cells were imaged at 37C, 5% CO2, using
a Leica LSM710 confocal microscope (488-nm excitation), and
GFP+ punctate autophagosomes were quantified by visual inspec-
tion in 50–60 cells per group before and after 4 hr of incubation
with bafilomycin (LC Laboratories). LC3 and p62 were further
quantified by western blot.
Western Blot
PiZZ or WT iPSCs were differentiated to T16 or T18 before treat-
mentwith either CBZ,DMSOvehicle, or regularmedia as described
for each experiment. Cell protein lysates were collected and sepa-
rated in a 12% polyacrylamide gel before transfer onto a polyviny-
lidene fluoride (PVDF) membrane. Membranes were probed with
antibodies against LC3 (Sigma-Aldrich), p62 (Abnova), B-actin
(Sigma-Aldrich), KDEL (Grp78 and Grp94; Enzo Life Sciences),
sXBP-1 (BioLegend), IkBa (Cell Signaling Technology), or GAPDH
(Millipore). Signal was detected using goat anti-mouse or anti-
rabbit HRP substrate (Bio-Rad) on a LAS-4000 luminescent image
analyzer (Fuji) and Image J software was utilized to measure
densitometry.
PSC Drug Treatment and Analysis
CBZ (Sigma-Aldrich) was added at the concentrations indicated in
the text to differentiation media. Cells, RNA, and supernatants
were collected 48 hr later for analysis by flow cytometry, qPCR,
ELISA, or western blot. To quantify the sensitivity of differentiating
iPSC-hepatic cells to hepatotoxic drugs, acetaminophen, aflatoxin
B, amiodarone, danazol, or puromycin was added to T20 differen-
tiation media at the indicated concentrations. Cell viability was
quantified after 4 hr (acetaminophen) or 4 days (aflatoxin B, amio-
darone, danazol, and puromycin) via MTT assay. For 4-day drug
exposures, media were changed once at the 48-hr time point.
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